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Abstract 
 Background: The chemokine receptor, CXCR7 is described to play a 
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biologically relevant role in tumor growth and spread.  Recently, it was 
reported   that CXCR7 overexpression is associated with an unfavorable 
prognosis and metastatis of epithelial ovarian cancer (EOC).  Aware that, 
several reports indicated  that Histone deacetylases (HDACs) regulate the 
expression and activity of many proteins involved in both cancer initiation 
and progression, the aim of this work,  was to study the effect of the HDAC 
inhibitor valproic acid (VPA) on the expression of CXCR7 as well as its 
impact on survival function in the epithelial ovarian cell line (SKOV-3).  
Methods: cells were cultured with varying concentrations of VPA (1, 2, 3, 4, 
5 and 10 mM) for different durations (0, 12 h, 24 h and 48 h). Cell survival 
was assessed by Neutral red assay and by colony counting which being 
stained with crystal violet. CXCR7 expression was determined at mRNA 
level using quantitative real-time PCR (qRT-PCR) or at the protein level 
using western blotting.  
Results: VPA reduces cell survival of SKOV-3 cancer cells. The inhibition 
effect of VPA was dose and time-dependent. Exposure to VPA at 
concentrations above 2 mM at 24 h resulted in an  increase expression of 
CXCR7 at both the mRNA and protein levels .  
Conclusion: These observations provide, for the first time, a better insight 
into the epigenetic mechanisms involved in regulating CXCR7 expression in 
EOC and will open new avenues for evaluating drugs that specifically 
stimulate the apoptosis of EOC with minimal unwanted side effects.  
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Introduction 
 Epithelial ovarian cancer (EOC) is the sixth most commonly 
diagnosed cancer among women in the word and the second most common 
gynecological cancer [1].  EOC is the fifth leading cause of death among 
women in developed countries due to the continued inability to detect early 
stage (I) disease [2]. Since, most women with EOC have disseminated 
disease (i.e. expansion in the abdominal cavity) at the time of diagnosis, 
chemotherapy  is needed to reduce the chance of recurrence. However, many 
patients gradually develop resistance to the drugs associated with their toxic 
effects. Hence, identifying some new agents that have better anticancer effect 
without being toxics is highly appreciated.  
 Accumulating evidences suggest that chemokines can affect tumour 
growth either directly, by acting as autocrine and/or paracrine growth factors 
or indirectly by promoting or inhibiting angiogenesis and inducing tumour 
metastasis. The best-characterized chemokine in this regard is 
CXCL12/SDF-1 which acts as an autocrine factor and proangiogenic inducer 
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of several cancers [3]. For many years it was thought that CXCR4 is the sole 
receptor for this chemokine.  However, in 2005, a second chemokine 
receptor, CXCR7, was identified , which binds to CXCL12 with high affinity 
[4,5]. CXCR7 also binds to a second chemokine, CXCL11/I-TAC, one of the 
ligands for CXCR3 [4]. The chemokine CXCL12 and its receptors, CXCR4 
and CXCR7, have been implicated in cancer progression and metastasis [6-
9]. Recent studies show an increase in the expression of CXCL12 and 
CXCR4/CXCR7 in different malignancies, including epithelial ovarian 
cancer and ovarian cancer cell lines [10-12]. Several  studies have also 
reported that treating cells with histone deacetylase inhibitors (HDI) 
treatment like valproic acid (VPA) results in an up-regulated expression of 
 many genes [13].  
 HDIs are potential anticancer agents because of their abilities to alter 
gene expression, induce apoptosis and growth arrest of tumor cells and 
stimulate differentiation [12]. It has been demonstrated that VPA could 
significantly inhibit the growth of various cancer cells including the 
epithelial ovarian cancer cells, in vivo, without toxic side effects [14, 15]. In 
this study we invetigated the effect of VPA on the viability of EOC cells 
derived from the EOC cell line, SKOV-3. Aware that only little is known, so 
far, about the mechanisms involved in regulating CXCR7 expression. 
However, a recent study reported that the histone deacetylase inhibitor (HDI) 
valproic acid (VPA) increases CXCR7 and CXCR4 expression in 
Mesenchymal stromal cells derived from cord blood [16]. For this reason, we 
investigated whether VPA enhances the expression of CXCR7 in the EOC 
cell line, SKOV-3.  
 
Materials and Methods 
Cells and Cell Culture 
 Human epithelial ovarian carcinoma cell line SKOV3 was purchased 
from the American Type Culture Collection (ATCC, Manassas, VA) and 
maintained in RPMI-1640 medium (Sigma Chemical Company) 
supplemented with 0.1mg/ ml streptomycin, 100 U/ml penicillin and 10% 
fetal bovine serum (FBS). SKOV-3 was maintained at 37 ° C, under an 
atmosphere containing 5% CO2. 
 
Neutral Red Analysis 
 Cell viability was performed using Neutral Red assay based on the 
initial protocol as described earlier [17, 18]. Neutral Red, a chromogenic 
dye, is an indicator of lysosomal activity. Live cells demonstrate a 
chromogenic change with Neutral Red that is detected 
spectrophotometrically. Briefly, cells were detached from the tissue culture 
flask with 2 ml of trypsin solution. The cell pellet was obtained by 
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centrifugation at 1.000 rpm for 5 minutes. The density of the viable cells was 
counted by the trypan blue exclusion in a haemocytometer. Cells were then 
plated in 96-well microtiter plate, at a concentration of 8 × 103
 
cells/well and 
incubated in a humidified 37°C, 5% CO2 incubator that allows the cells to 
adhere. After 24 h, the cells were treated with six different concentrations of 
Valproic acid (VPA): 1, 2, 3, 4, 5 and 10 mM each being tested in three 
replicates. VPA were purchased from Sigma-Aldrich. The plates were 
incubated for 24 and 48 h at 37°C in a 5% CO2 incubator. The untreated 
cells were regarded as a negative control, whilst cells incubated only with 
ethanol (0.5%, v/v) were used as a vehicle control. No effect due to the 
ethanol was observed. At 24 and 48 h, the old medium was replaced with 
100 𝜇l of fresh medium containing 40 𝜇g/ml neutral red and incubated for 3 
h. This is to allow the uptake of the vital dye into the lysosomes of viable 
and undamaged cells. Then, the media was discarded and cells were washed 
twice with 100 𝜇l of 1X PBS. The intracellular accumulation of neutral red 
dye was extracted in 200 μl of a 50% ethanol-1% acetic acid lysing solution. 
 The optical density (OD) of the eluted dye was read at 490 nm using 
a microplate reader. The experiments were conducted in triplicates. The 
percentage of inhibition of each of the test samples was calculated according 
to the following formula using the OD values obtained: Percentage of 
inhibition (%) = (OD control − OD sample)/OD control × 100. 
 
Focus formation assay- Staining of colonies 
 One hundred cells/well were seeded in 6-well plates and incubated at 
37°C, 5% CO2 for 24 hours. Following a 24-hour incubation, various 
concentrations of VPA were added for different durations (0, 12 h, 24 h and 
48 h). After 10 days, the content of each well was removed and the colonies 
were washed twice with 500 μL of sterilized water, to remove cells weakly 
adhered. The attached colonies was quantified using crystal violet staining at 
5mg/ml in 25% methanol [19-21]. Briefly, 500 μL of a solution sodium 
acetate/formalin 2% were distributed in each well, in order to fix the adhered 
cells, and left for 15 min. After this time, the solution sodium 
acetate/formalin 2% was removed and 500 μL of crystal violet were added to 
each well. After approximately 20-30 min, the stain was removed by 
washing the wells three times under cold water and the plates were left at 
room temperature to dry before colony counting. The colony formation are 
counted manually with naked eye. 
 
Total RNA extraction 
2 × 105
 
cells/well were seeded in 6-well plates and incubated at 37°C, 5% 
CO2 for 24 hours. Following a 24-hour incubation, various concentrations of 
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VPA (1, 2, 3, 4 and 5 mM) were added for different durations (0, 12 h, 24 h 
and 48 h). Cell line was homogenized using TriPure reagent (Roche, USA) 
following the manufacturer's instructions. After complete dissociation of 
nucleoprotein complexes, phase separation was achieved with chloroform 
and centrifugation. The precipitated RNA from the aqueous phase was 
washed with 75% ethanol. The RNA was dried and dissolved in RNase-free 
water. The amount and quality of the extracted RNA were assessed by 
spectrophotometry using NanoDrop. 
 
Western blot analysis 
 SKOV-3 cells were seeded at 0.7 x 106 per 25 cm2 plate overnight. 
The next day VPA was added to cells at various concentrations (2.5, 5, 10 
mM) for 24 h. Total cell lysate was prepared using the lysis buffer RIPA 
(150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, 50 mM 
Tris, pH 8, 20 mM, NaF, 2 mM EGTA, 0.5% levamisole, 1 mM NaVO4) 
(Roche). Protein concentration was determined using Bradford method (Bio-
Rad). The protein complexes were separated on 10% gradient SDS-PAGE 
gel. Membrane was incubated with CXCR7 (Sigma) and GAPDH (Sigma) 
primary antibodies. Proteins were detected using ECL detection kit (Bio- 
Rad) according to the manufacturer’s protocol. The immune complexes were 
visualized with the use of the ECL Plus kit (Amersham) according to the 
manufacturer’s protocol. The autoradiographs obtained were scanned and the 
band intensity quantified utilizing TotalLab software (Nonlinear Dynamics, 
Newcastle on Tyne, UK). All bands were normalized with respect to 
GAPDH. 
 
Quantitative RT-PCR studies 
 Total RNA was isolated from SKOV-3 cells treated with 1, 2, 3, 4 
and 5 mM VPA for different durations (0, 12 h, 24 h and 48 h). First strand 
cDNA was synthesized with 1 μg of total RNA using kit iScriptTM (Bio- 
Rad). We amplified the resulting cDNA by real-time PCR on a Bio- Rad 
Mini Opticon real-time PCR system, with the IQ SYBR green supermix kit 
(Bio-Rad). The data were analyzed with Opticon Monitor 3 software (Bio-
Rad). EF-1 alpha was used to normalize samples. The primers used were as 
follows: CXCR7 (forward: 55-’TGCATCTCTTCGACTACTCAGA- 3’, 
reverse: 5’ GGCATGTTGGGACACATCAC-3’) and EF-1 alpha (forward: 
5’- CTGAACCATCCAGGCCAAAT- 3’, reverse: 5’- 
GCCGTGTGGCAATCCAAT- 3’). 
 
Statistical analysis  
 All results were presented as mean ± standard error of the mean 
(SEM). Statistical analyses were performed using GraphPad Prism 5 
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(GraphPad Software Inc., CA, USA). Two-way ANOVA was used to 
calculate 𝑃 values (p). Groups that are significantly different from control 
are indicated in the figures as * p < 0.05, ** p < 0.01 and *** p < 0.001. 
 
Results 
VPA reduces cell survival of SKOV-3 cancer cells 
 Previous studies suggest that VPA is effective on EOC cell lines [14]; 
therefore we examined its effect on SKOV-3 cells [14, 22]. First we tested 
whether VPA could have any effect on SKOV-3 cell growth.  
 Upon using the Neutral Red Cytotoxicity/ Viability Assay to measure 
the viability of the SKOV-3 cells, an evaluation of the antiproliferative 
activity of various concentrations of VPA (1, 2, 3, 4, 5 and 10 mM) was 
performed after 24 and 48 hours of treating this cancerous cell line. The 
neutral red assay shows that the VPA has no significant antiproliferative 
effect after 24 h and 48 h of treatment at a concentration of 1 or 2 mM. The 
percentage of survival inhibition was increased by 13-fold after 24 h and by 
23-fold after 48 h of treatment with 3 mM VPA (Figures 1and 2). The 
percentage of survival inhibition reached 19, 28 and 44-fold increase, at the 
concentration of 4, 5 and 10 mM, respectively after 24 h of VPA treatment 
(Figure 1 and 2A).  VPA  also significantly increased the percentage of 
survival inhibition after 48 h by 45-fold and 60-fold at the concentration of 4 
and 5 mM of VPA, respectively (Figure 1 and 2B) . The highest 
antiproliferative activity (p<0.001) on the SKOV-3 cell line was 73-fold 
increase at 10 mM VPA after 48 h (Figure 1 and 2B) . The percentage of 
survival inhibition was compared to untreated cells. The antiproliferative 
activity was further confirmed by another technique based on colony 
counting which being stained with crystal violet.  
 SKOV-3 cells did not show significant effects in colony formation 
after 12 h of VPA treatment with 1, 2, 3, 4 and 5 mM (Figures 3A and 4). 
When treated with 3, 4 and 5 mM VPA at 24 h, SKOV-3 cells showed 
significant decrease in colony formation (p<0.001) by 73-fold, 74-fold and 
89-fold, respectively (Figures 3B and 4). When treated with 2, 3 and 4 mM 
VPA at 48 h, SKOV-3 cells showed significant decrease in colony formation 
by 79-fold, 82-fold and 83-fold, respectively (Figures 3C and 4). The highest 
inhibition activity of SKOV-3 colony formation (p<0.001) is 95-fold with 5 
mM VPA at 48 h (Figure 3C and 4) . The inhibition of colony formation was 
compared to untreated cells. Taken together these data suggest that this drug 
inhibits cell viability of SKOV-3 in a dose- and time- dependent manner 
(Figures 1-4).  
 
VPA Increases the Gene and Protein Expression of CXCR7 in SKOV-3  
Next, we tested the effect of VPA on CXCR7  mRNA/protein 
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expression. Western blot assay revealed that CXCR7 protein was induced 
with 2.5 mM TSA at 24 h (Figure 5). The induction of CXCR7 mRNA was 
further confirmed with quantitative RT-PCR. The result of quantitative RT-
PCR shows that the VPA has no significant effect in CXCR7 mRNA 
expression after 24 and 48 h of treatment at 2, 3, 4 and 5 mM (Figure 6). 
 Likewise, 1 mM VPA has no significant effect in CXCR7 mRNA expression 
after 48 h of treatment (Figure 6). Four-fold induction of CXCR7 mRNA at 
1mM VPA was observed after 12 h treatment (Figure 6). We observed nine-
fold induction of CXCR7 mRNA at 3 mM VPA, two-fold increase induction 
at 4 mM VPA and seven-fold increase induction at 5 mM after 48 h 
treatment (Figure 6), suggesting that VPA activates CXCR7 transcription. 
These results are consistent with the induction of CXCR7 by VPA in blood 
mesenchymal stromal cells [16, 23].  
 Figure 1: Valproic acid (VPA) affect the survival of the SKOV3 cells.  
 
 The SKOV3 cells were incubated with different concentrations of 
VPA (1, 2, 3.4, 5 and 10 mM) for 24 and 48 hours. Cell viability was 
estimated by the neutral red (NR) test. The harvested cells are exposed to the 
dye (NR). The cells are lysed and the optical density (OD) is measured at 
490 nm. % Inhibition = OD (optical density) of non-treated cells - OD of 
treated cells / OD of non-treated cells × 100. Results represent % inhibtion of 
cell survival of SKOV3 cells compared to control. Experiments were done in 
triplicates and results represent the mean ± SEM of three independent 
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experiments. * p <0.05; ** P <0.01; *** P <0.001 (Two-way ANOVA). 
Figure 2: Microscopic view of SKOV-3 cells after 24 (A) and 48 hours (B) incubation with 
increasing concentrations (1, 2, 3, 4, 5 and 10 mM) of VPA. The results presented are from 
one experiment representative of three carried out, and were photographed with a 
microscope (× 40). 
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Figure 3:  Cell colonies (SKOV3) formed after VPA treatment. SKOV-3 was treated 
with 0 (control), 1, 2, 3, 4 or 5 mM of VPA for 12 (A), 24 (B) or 48 h (C). After 10 days, 
colonies were stained with crystal violet. The colony formation are counted manually with 
naked eye. 
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Figure 4: Treatment with valproic acid (VPA) affects the clonogenic survival of the 
SKOV3 cells. SKOV3 cells were incubated with different concentrations of VPA (1, 2, 3.4 
and 5 mM) for 12, 24 and 48 hours. Clonogenic survival was made by counting cell 
colonies. The colony formation on the 6-well plates seeded with 100 cells after 10 days, are 
counted manually with naked eye after staining with crystal violet. Results 
represent the number of clones of SKOV3 cells compared to control. Error 
bars represent standard error of the mean (SEM).  * p <0.05; ** P <0.01; *** 
P <0.001 (Two-way ANOVA). 
 
 
 
 
Figure 5: Effect of VPA on the protein expression of CXCR7. Whole cell lysate of 
SKOV-3 was prepared after 24 hours of exposure to VPA (2.5, 5 and 10 mM). The proteins 
were extracted in RIPA as described in the Materials and methods. 100 µg of each extraction 
were loaded into separate lanes of a 10% SDS-polyacrylamide gel electrophoresis and after 
transfer to nitrocellulose membranes were probed with antibodies against CXCR7. GAPDH 
was used as a control to ensure equal loading. 
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Figure 6: Effect of VPA on the expression of CXCR7 mRNA. CXCR7 mRNA levels 
were quantified by real-time PCR and are expressed as CXCR7 content normalized to that 
of EF-1 alpha. The cells were treated or not with 1, 2, 3, 4 and 5 mM VPA for 12, 24, 48 
hours. Error bars represent standard error of the mean (SEM).  * p <0.05 (Two-way 
ANOVA). 
 
Discussion  
 Ovarian cancer is the fifth most deadly cancer in women [2]. 
Chemotherapy is effective against advanced ovarian cancer, but this 
treatment must be adjusted because of its serious side effects. Therefore, 
identifying new treatments with better anticancer effect without toxicities are 
highly needed. With the development of agents with epigenetic effects 
involved in transcriptional regulation , cell growth, apoptosis, differentiation 
and proliferation, researchers started to seriously study these agents as a 
potential new cancer treatment [12].  
 Deregulated activity of histone deacetylases (HDAC) is usually 
observed in many cancer types. T reatment with HDAC inhibitors (HDACIs) 
can suppress cell proliferation and differentiation and induce apoptosis of 
ovarian cancer cells suggesting that HDACs are required to maintain cancer 
cell survival [24-26]. However, the role of HDAC inhibitors in  regulating 
gene transcription that support tumor properties is poorly understood. Some 
studies show that the anti-proliferative activity of HDACIs is a result of cell 
cycle arrest in G1 that is associated with the increased expression of the 
cyclin-dependent kinase (cdk) inhibitor p21WAF1/CIP1 [27-28]. Among 
different HDACIs, valproic acid (VPA) is most commonly studied for its 
effect on  cell growth arrest [29].  
 Valproic acid has been widely used in the treatment of seizure 
disorders and for the treatment of bipolar depressive and epileptic illness 
[30]. A new study shows that VPA, even at low concentration, serve as an 
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effective inhibitor of HDACs. VPA can interrupt tumor angiogenesis and 
metastasis of EOC by down regulating the VEGF protein and up-regulating 
E-cadherin protein and MMP-9 protein [14]. In vivo, the role of VPA 
becomes very important especially in the inhibition of cancer cell migration, 
angiogenesis and invasion [31-33]. A recent study shows that VPA can 
significantly inhibit the growth of the epithelial ovarian cancer cells in vivo; 
this antitumor activity was not accompanied by any major side effects [14]. 
Such observation enabled us to check whether VPA could have similar 
effects on the survival of EOC cell lines, SKOV-3. 
 The standard treatment for ovarian cancer is surgery followed by 
platinum based chemotherapy (e.g., DDP or cisplatin). This treatment is 
associated with high response rates. However, the disease is characterized by 
recurrence and the subsequent development of resistance to chemotherapy 
[34]. Some studies showed that HDACIs increase the efficiency of several 
anticancer drugs that target the DNA [35-37].  Interestingly, one report [38] 
indicated that VPA exhibits synergistic cytotoxicity with cisplatin and can 
also resensitize the cells that have acquired resistance to cisplatin in all of the 
ovarian carcinoma cells tested. The cotreatment with VPA was shown to 
upregulate the cisplatin-mediated DNA damage [38].  
 In this study we found that the viability of SKOV3 cells was 
significantly inhibited by VPA in a dose and time dependent. Our study 
shows that the VPA has an antiproliferative effect on cancer cells. Because 
so little is known about the anticancer mechanisms triggered by VPA, future 
studies are necessary to better understand the mechanism of cell death 
induction by VPA.  
 Chemokines are important in the pathogenesis of several tumors. 
Early studies demonstrated an evident correlation between the expression of 
chemokine receptors and the tumor growth, angiogenesis, and metastasis in 
various human malignant tumors. The chemokine SDF-1 and its receptors, 
CXCR4 and CXCR7, are implicated in cancer progression, angiogenesis and 
metastasis [6-9]. Recent studies reported an increase in the expression of 
CXCL12 and CXCR4/CXCR7 in different malignancies, including epithelial 
ovarian cancer and ovarian cancer cell lines [10-12]. Several  studies have 
also reported  an up-regulated expression of  many genes after treating cells 
with a histone deacetylase inhibitor (HDI) like VPA [13]. However, how 
these HDAC inhibitors affect the transcriptional network that sustain tumor 
properties is still poorly understood. A recent study reported that valproic 
acid (VPA) increases CXCR7 and CXCR4 expression in Mesenchymal 
stromal cells derived from cord blood [16]. For this reason, we decided to 
study the effect of valproic acid on CXCR7 gene expression in the EOC cell 
line, SKOV-3. Our results revealed that the expression levels of CXCR7  
protein /mRNA were significantly enhanced in the presence of 2.5 to 3 mM 
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VPA for 24 h. This study suggests that VPA could be a potentail and novel 
attractive agent for treatment of epithelial ovarian cancer.  
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